{
  "id": "24cedea2c3d85f02",
  "title": "Akari Therapeutics Issues 2025 End of Year Letter to Shareholders",
  "description": "20251230T144500Z",
  "content": "",
  "source": "manilatimes.net",
  "source_url": "https://www.manilatimes.net/2025/12/30/tmt-newswire/globenewswire/akari-therapeutics-issues-2025-end-of-year-letter-to-shareholders/2251043",
  "published_at": "20251230T144500Z",
  "fetched_at": "2025-12-31T00:23:34.453563+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [],
  "location": "Philippines",
  "raw_data": {
    "url": "https://www.manilatimes.net/2025/12/30/tmt-newswire/globenewswire/akari-therapeutics-issues-2025-end-of-year-letter-to-shareholders/2251043",
    "url_mobile": "https://www.manilatimes.net/2025/12/30/tmt-newswire/globenewswire/akari-therapeutics-issues-2025-end-of-year-letter-to-shareholders/2251043/amp",
    "title": "Akari Therapeutics Issues 2025 End of Year Letter to Shareholders",
    "seendate": "20251230T144500Z",
    "socialimage": "https://www.manilatimes.net/manilatimes/uploads/images/2025/12/30/883673.jpg",
    "domain": "manilatimes.net",
    "language": "English",
    "sourcecountry": "Philippines"
  }
}